Kalaris Therapeutics Inc(KLRS)Earnings, Financials & Key Ratios
KLRS•NASDAQ
Price updated Jun 11, 2026
AboutKalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.Show more
- Revenue$0
- EBITDA-$46M+21.5%
- Net Income-$43M+26.1%
- EPS (Diluted)-2.85+75.7%
- ROE-45.22%+73.7%
- Debt/Equity0.02
- Interest Coverage-31.98
KLRS Key Insights
Kalaris Therapeutics Inc (KLRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KLRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KLRS Price & Volume
Kalaris Therapeutics Inc (KLRS) stock price & volume — 10-year historical chart
Loading chart...
KLRS Growth Metrics
Kalaris Therapeutics Inc (KLRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM82.04%
Return on Capital
10 Years-41.04%
5 Years-51.57%
3 Years-69.51%
Last Year-40.96%
KLRS Recent Earnings
Kalaris Therapeutics Inc (KLRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (70%)
Q2 2026Latest
May 12, 2026EPS
$0.46
Est $0.52
+11.5%
Revenue
—
Q2 2026
Mar 17, 2026EPS
$0.44
Est $0.56
+21.4%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.64
Est $0.66
+3.0%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.61
Est $0.51
-19.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.46vs $0.52+11.5% | — |
| Q2 2026 | Mar 17, 2026 | $0.44vs $0.56+21.4% | — |
| Q4 2025 | Nov 12, 2025 | $0.64vs $0.66+3.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.61vs $0.51-19.6% | — |
Based on last 12 quarters of dataView full earnings history →
KLRS Peer Comparison
Kalaris Therapeutics Inc (KLRS) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REPL | 711.78M | 8.62 | -2.81 | -102.69% | 0.18 | |||
 ADMA | 1.93B | 8.32 | 13.87 | 19.63% | 32.43% | 38.97% | 0.17 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare KLRS vs Peers
Kalaris Therapeutics Inc (KLRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KLRS Income Statement
Kalaris Therapeutics Inc (KLRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.14M | 165K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -85.46% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 73K | 1.12M | 0 | 0 | 0 | 13K | 20K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -73K▲ 0% | -1.12M▼ 1430.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -13K▲ 0% | -20K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | -1430.14% | 100% | - | - | - | - |
Operating Expenses | 4.73M | 26.85M | 71.24M | 168.7M | 14.01M | 13.46M | 55.26M | 46.14M | 47.61M |
OpEx % of Revenue | 416.83% | 16270.91% | - | - | - | - | - | - | - |
Selling, General & Admin | 3.03M | 10.62M | 21.65M | 49.08M | 2.24M | 1.76M | 42.92M | 15.39M | 15.32M |
SG&A % of Revenue | 267.05% | 6435.15% | - | - | - | - | - | - | - |
Research & Development | 1.7M | 16.23M | 49.59M | 119.62M | 11.76M | 11.71M | 12.34M | 30.75M | 32.3M |
R&D % of Revenue | 149.78% | 9835.76% | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -3.6M▲ 0% | -26.7M▼ 642.5% | -71.31M▼ 167.1% | -169.82M▼ 138.1% | -14.01M▲ 91.8% | -13.46M▲ 3.9% | -55.26M▼ 310.4% | -46.15M▲ 16.5% | -47.63M▲ 0% |
Operating Margin % | -316.83% | -16182.42% | - | - | - | - | - | - | - |
Operating Income Growth % | - | -642.52% | -167.06% | -138.14% | 91.75% | 3.87% | -310.4% | 16.48% | - |
EBITDA | -2.43M | -26.68M | -71.24M | -168.7M | -15.25M | -14.01M | -58.77M | -46.14M | -45.87M |
EBITDA Margin % | -214.1% | -16170.91% | - | - | - | - | - | - | - |
EBITDA Growth % | - | -998.02% | -166.98% | -136.82% | 90.96% | 8.12% | -319.42% | 21.49% | 15.84% |
D&A (Non-Cash Add-back) | 0 | 19K | 73K | 1.12M | 0 | 0 | 0 | 13K | 10K |
EBIT | -2.43M | -23.84M | -69.78M | -170.96M | -15.25M | -14.01M | -58.77M | -46.15M | -45.88M |
Net Interest Income | 56K | 2.06M | 1.33M | 1.31M | -235K | -687K | 5.49M | -1.44M | 0 |
Interest Income | 56K | 2.06M | 1.33M | 1.31M | 0 | 0 | 5.49M | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 235K | 687K | 0 | 1.44M | 0 |
Other Income/Expense | 1.17M | 2.86M | 1.52M | -1.14M | -1.48M | -1.24M | -3.51M | 2.71M | 3.53M |
Pretax Income | -2.43M▲ 0% | -23.84M▼ 881.0% | -69.78M▼ 192.7% | -170.96M▼ 145.0% | -15.48M▲ 90.9% | -14.7M▲ 5.1% | -58.77M▼ 299.8% | -43.44M▲ 26.1% | -44.1M▲ 0% |
Pretax Margin % | -214.1% | -14447.88% | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 1.01M | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | -0.59% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.43M▲ 0% | -23.84M▼ 881.0% | -69.78M▼ 192.7% | -171.96M▼ 146.4% | -15.48M▲ 91.0% | -14.7M▲ 5.1% | -58.77M▼ 299.8% | -43.44M▲ 26.1% | -44.1M▲ 0% |
Net Margin % | -214.1% | -14447.88% | - | - | - | - | - | - | - |
Net Income Growth % | - | -881.03% | -192.73% | -146.42% | 91% | 5.08% | -299.82% | 26.09% | 23.09% |
Net Income (Continuing) | -2.43M | -23.84M | -69.78M | -171.96M | -15.48M | -14.7M | -58.77M | -43.44M | -44.1M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.88▲ 0% | -8.42▼ 192.4% | -59.67▼ 608.7% | -63.00▼ 5.6% | -50.62▲ 19.6% | -42.09▲ 16.9% | -11.73▲ 72.1% | -2.85▲ 75.7% | -1.86▲ 0% |
EPS Growth % | - | -192.36% | -608.67% | -5.58% | 19.65% | 16.86% | 72.13% | 75.7% | 82.04% |
EPS (Basic) | -2.88 | -8.42 | -59.67 | -63.00 | -50.62 | -42.09 | -11.73 | -2.85 | - |
Diluted Shares Outstanding | 2.83M | 2.83M | 1.17M | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M | 23.72M |
Basic Shares Outstanding | 2.83M | 2.83M | 1.17M | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M | 23.72M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KLRS Balance Sheet
Kalaris Therapeutics Inc (KLRS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.31M | 127.31M | 361.32M | 253.35M | 3.9M | 3.33M | 118.55M | 118.81M | 98.08M |
Cash & Short-Term Investments | 24.96M | 126.08M | 356.32M | 248.12M | 3.06M | 3.17M | 118.29M | 117.98M | 97.22M |
Cash Only | 24.96M | 61.08M | 122.66M | 201.66M | 3.06M | 3.17M | 118.29M | 98.05M | 34.43M |
Short-Term Investments | 0 | 64.99M | 233.66M | 46.46M | 0 | 0 | 0 | 19.93M | 62.79M |
Accounts Receivable | 302K | 560K | 450K | 50K | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 97.12 | 1.24K | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 51K | 676K | 4.54M | 5.18M | 0 | 0 | 257K | 78K | 861K |
Total Non-Current Assets | 6K | 12.11M | 9.5M | 33.25M | 0 | 0 | 0 | 2.93M | 11.73M |
Property, Plant & Equipment | 0 | 12.11M | 9.5M | 31.29M | 0 | 0 | 0 | 1.48M | 1.43M |
Fixed Asset Turnover | - | 0.01x | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 852K | 0 | 0 | 0 | 499K | 8.65M |
Other Non-Current Assets | 6K | 0 | 0 | 1.1M | 0 | 0 | 0 | 953K | 2.14M |
Total Assets | 25.32M▲ 0% | 139.42M▲ 450.7% | 370.82M▲ 166.0% | 286.59M▼ 22.7% | 3.9M▼ 98.6% | 3.33M▼ 14.5% | 118.55M▲ 3456.7% | 121.74M▲ 2.7% | 109.81M▲ 0% |
Asset Turnover | 0.04x | 0.00x | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 450.66% | 165.97% | -22.71% | -98.64% | -14.52% | 3456.74% | 2.69% | 3175.85% |
Total Current Liabilities | 3.74M | 9.11M | 12.29M | 37.85M | 5.69M | 3.94M | 5.24M | 9.71M | 8.08M |
Accounts Payable | 153K | 630K | 963K | 8.36M | 2.76M | 2.36M | 247K | 1.28M | 905K |
Days Payables Outstanding | - | - | 4.82K | 2.73K | - | - | - | 35.97K | 29.02K |
Short-Term Debt | 0 | 3.07M | 3.23M | 6.59M | 0 | 0 | 0 | 316K | 317K |
Deferred Revenue (Current) | 2.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 921K | 3.89M | 4.79M | 15.03M | 296K | 540K | 1.96M | 6.52M | 6.86M |
Current Ratio | 6.77x | 13.98x | 29.39x | 6.69x | 0.69x | 0.85x | 22.63x | 12.23x | 12.14x |
Quick Ratio | 6.77x | 13.98x | 29.39x | 6.69x | 0.69x | 0.85x | 22.63x | 12.23x | 12.14x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 8.69M | 5.46M | 23.48M | 28.48M | 44.41M | 0 | 33.21M | 33.17M |
Long-Term Debt | 0 | 0 | 0 | 0 | 3.25M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 8.69M | 5.46M | 23.48M | 0 | 0 | 0 | 1.13M | 3.39M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 25.23M | 44.41M | 0 | 32.08M | 32.08M |
Total Liabilities | 3.74M | 17.8M | 17.76M | 61.33M | 34.17M | 48.35M | 5.24M | 42.92M | 41.25M |
Total Debt | 0 | 11.76M | 8.69M | 30.07M | 3.25M | 0 | 0 | 1.45M | 1.41M |
Net Debt | -24.96M | -49.33M | -113.97M | -171.59M | 194K | -3.17M | -118.29M | -96.61M | -33.02M |
Debt / Equity | - | 0.10x | 0.02x | 0.13x | - | - | - | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.72x |
Interest Coverage | - | - | - | - | -64.89x | -20.40x | - | -31.98x | - |
Total Equity | 21.58M▲ 0% | 121.62M▲ 463.5% | 353.06M▲ 190.3% | 225.27M▼ 36.2% | -30.27M▼ 113.4% | -45.02M▼ 48.7% | 113.31M▲ 351.7% | 78.81M▼ 30.4% | 68.56M▲ 0% |
Equity Growth % | - | 463.54% | 190.29% | -36.2% | -113.44% | -48.71% | 351.7% | -30.44% | 98.33% |
Book Value per Share | 7.62 | 42.97 | 301.91 | 82.53 | -9.08 | -9.95 | 22.62 | 5.16 | 2.89 |
Total Shareholders' Equity | 21.58M | 121.62M | 353.06M | 225.27M | -30.27M | -45.02M | 113.31M | 78.81M | 68.56M |
Common Stock | 0 | 0 | 7K | 7K | 0 | 0 | 0 | 2K | 2K |
Retained Earnings | -31.48M | -55.32M | -125.1M | -297.06M | -32.7M | -47.39M | -714.96M | -160M | -170.85M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 68K | -112K | -155K | 0 | 0 | -135K | 6K | -49K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KLRS Cash Flow Statement
Kalaris Therapeutics Inc (KLRS) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.94M | -20.16M | -60.81M | -106.32M | -9.78M | -14.13M | -67.7M | -42.98M | -48.88M |
Operating CF Margin % | 171.19% | -12215.15% | - | - | - | - | - | - | - |
Operating CF Growth % | - | -1137.31% | -201.72% | -74.84% | 90.8% | -44.51% | -379.09% | 36.52% | -516.17% |
Net Income | -2.43M | -23.84M | -69.78M | -171.96M | -15.48M | -14.7M | -58.77M | -43.44M | -44.1M |
Depreciation & Amortization | 0 | 19K | 73K | 1.12M | 0 | 0 | 0 | 13K | 20K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 271K | 148K | 0 | 0 | 638K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 967K | 2.27M | 9.93M | 45.17M | 2.04M | 1.51M | 16.37M | -2.98M | -5.39M |
Working Capital Changes | 3.41M | 1.4M | -1.03M | 19.35M | 3.4M | -1.09M | -25.3M | 3.43M | -53K |
Change in Receivables | 170K | -258K | 110K | 400K | 0 | 0 | 206K | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 601K | 4.94M | 2.73M | 20.29M | 1.83M | -402K | -28.86M | -88K | -1.4M |
Cash from Investing | 0 | -64.64M | -169.5M | 185.98M | 0 | 0 | 95M | -19.72M | -70.07M |
Capital Expenditures | 0 | -339K | -235K | -26K | 0 | 0 | 0 | -200K | -200K |
CapEx % of Revenue | - | 205.45% | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 22.87M | 120.92M | 291.98M | 232K | 12.78M | 14.24M | 21K | 159.61M | 52.42M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 4.3M | 6M | 0 | 7.5M | 7.5M |
Equity Issued (Net) | 22.87M | 120.92M | 291.98M | 232K | 8.47M | 6.74M | 21K | 50M | 50.07M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 5K | 1.5M | 0 | 102.11M | -5.15M |
Net Change in Cash | 24.96M▲ 0% | 36.12M▲ 44.7% | 61.58M▲ 70.5% | 79M▲ 28.3% | 3M▼ 96.2% | 110K▼ 96.3% | 28.17M▲ 25507.3% | -20.23M▼ 171.8% | -66.54M▲ 0% |
Free Cash Flow | 1.94M▲ 0% | -20.49M▼ 1154.8% | -61.05M▼ 197.9% | -106.34M▼ 74.2% | -9.78M▲ 90.8% | -14.13M▼ 44.5% | -67.7M▼ 379.1% | -43.18M▲ 36.2% | -49.09M▲ 0% |
FCF Margin % | 171.19% | -12420.61% | - | - | - | - | - | - | - |
FCF Growth % | - | -1154.76% | -197.87% | -74.2% | 90.8% | -44.51% | -379.09% | 36.23% | -142.28% |
FCF per Share | 0.69 | -7.24 | -52.20 | -38.96 | -2.93 | -3.12 | -13.52 | -2.83 | -2.07 |
FCF Conversion (FCF/Net Income) | -0.80x | 0.85x | 0.87x | 0.62x | 0.63x | 0.96x | 1.15x | 0.99x | 1.11x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KLRS Key Ratios
Kalaris Therapeutics Inc (KLRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -33.29% | -29.4% | -59.47% | -15.88% | - | -172.12% | -45.22% | -72.78% |
| Return on Invested Capital (ROIC) | -58.11% | -34.35% | -87.01% | -89.05% | - | - | - | 863.92% |
| Net Margin | -14447.88% | - | - | - | - | - | - | - |
| Debt / Equity | 0.10x | 0.02x | 0.13x | - | - | - | 0.02x | 0.02x |
| Interest Coverage | - | - | - | -64.89x | -20.40x | - | -31.98x | - |
| FCF Conversion | 0.85x | 0.87x | 0.62x | 0.63x | 0.96x | 1.15x | 0.99x | 1.11x |
| Revenue Growth | -85.46% | -100% | - | - | - | - | - | - |
Related:KLRS Dividend History·KLRS Revenue History·KLRS Price History·KLRS P/E History·KLRS Financial Ratios·KLRS Institutional Holders
KLRS Frequently Asked Questions
Kalaris Therapeutics Inc (KLRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kalaris Therapeutics Inc (KLRS) grew revenue by 0.0% over the past year. Growth has been modest.
Kalaris Therapeutics Inc (KLRS) reported a net loss of $44.1M for fiscal year 2025.
Dividend & Returns
Kalaris Therapeutics Inc (KLRS) has a return on equity (ROE) of -45.2%. Negative ROE indicates the company is unprofitable.
Kalaris Therapeutics Inc (KLRS) had negative free cash flow of $49.1M in fiscal year 2025, likely due to heavy capital investments.